PPT-Effect of Remdesivir on Clinical Status in Patients With Moderate COVID-19 (Multinational)

Published Data Randomized openlabel trial Source Spinner CD et al JAMA 2020324104857 Effect of Remdesivir on Clinical Status in Patients With Moderate COVID19 Design 1 Source Spinner CD et al JAMA 2020324104857. COVID-19 Clinical GuidanceFor the CVCare Team1COVID-19Clinical Guidance For the Cardiovascular Care TeamNoteCOVID-19 is a quickly evolving public health emergency The guidance provided in this documen 1Children MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19Developed by the ACR MIS-C and COVID-19 Related Hyperinflammation Task ForceThis summary was approved by the ACR Board of Di COVID-19 Vaccine Summaryfor Patients with Rheumatic and Musculoskeletal DiseasesDeveloped by the ACR COVID-19 Vaccine Clinical Guidance Task ForceThissummary was initially approved by the ACR Board of Anthony Allen Reeves, Subrata Deb* . Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA. *. Corresponding author: Dr. Subrata Deb, E-mail: . sdeb@alumni.ubc.ca. Martina Andellini. martina.andellini@warwick.ac.uk. , . University of Warwick, Coventry, UK. martina.andellini@opbg.net. , . Bambino Gesù Children’s Hospital, Rome, Italy. The Team. Leandro Pecchia . centres. Case Management Team. , . WHE/WHO, HQ Geneva . Classification of severity of patients with COVID-19 . infection. See WHO website for most up-to-date case definition: . https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance. John Veillette, PharmD, BCPS. Col. Todd J. Vento, MD, MPH, FACP, FIDSA, ID-DUDE. 6/24/20. Outline. Virologic Therapies. Hydroxychloroquine. Remdesivir. Convalescent plasma. Immunologic Therapies. Tocilizumab. M. Safwan Badr, MD, MBA. Professor and Chair, Department of Internal Medicine. Wayne State University School of Medicine.. Pathophysiology of COVID. Coronaviruses. Large, enveloped, single-stranded RNA viruses found in humans and other mammals. Raj Dasgupta MD, FACP, FCCP, FAASM. Associate Professor of Clinical Medicine. Assistant Program Director of Internal Medicine Residency. Associate Program Director of Sleep Medicine Fellowship. Department of Pulmonary / Critical Care / Sleep Medicine. Speakers. Dr Jonathan . Grein. - . Cedars-Sinai Medical Center, L.A.. Dr Shariq Haider- McMaster University. Moderator. Dr Curtis Cooper- University of Ottawa. Our Mission. The Canadian Foundation for Infectious Diseases is a charitable organization committed to improving the health of Canadians and people worldwide through the support of research and dissemination of knowledge pertaining to the prevention, diagnosis, control and treatment of infectious diseases.. This webinar is being recorded and will be posted to the CTTI website. All participants are muted upon entry. Questions can be entered in the chat box during the webinar. Questions will be answered to the best of our ability after the call via CTTI’s best practices document. Paediatrician . Southland Hospital. Clinical features. Asymptomatic in one third. Mild symptoms in most others. Rarely deteriorate after day 5 of illness. PIMS-TS rare complication can occur up to 6 weeks after COVID-19. Constance A. Benson, MD. Professor of Medicine and Global Public Health. University of California San Diego. La Jolla, California. Financial Relationships With Commercial Entities. Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to . Peter Chin-Hong, MD. Professor of Medicine. University of California San Francisco. San Francisco, California . Financial Relationships With Ineligible Companies . (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:.